{
    "url_original": "https://www.wsj.com/articles/biogen-investigates-death-of-aduhelm-patient-11636479862?mod=business_lead_pos12",
    "url": "biogen-investigates-death-of-aduhelm-patient-11636479862",
    "title": "Biogen Investigates Death of Aduhelm Patient",
    "sub_head": "Company is exploring whether the death of the 75-year-old, who experienced brain swelling, is linked to use of the Alzheimer’s drug",
    "category_1": "Business",
    "category_2": "Health Care",
    "image_1_url": "https://images.wsj.net/im-431746?width=860&height=573",
    "image_1": "im-431746.jpg",
    "time": "2021-11-09 12:44:00",
    "body": "Biogen Inc. said it is investigating the recent death of a 75-year-old patient who had taken the company’s new Alzheimer’s drug Aduhelm.<br />After taking Aduhelm, the patient was hospitalized and diagnosed with swelling in the brain before dying. It isn’t known yet whether the brain swelling was related to Aduhelm, Biogen said Tuesday."
}